285 related articles for article (PubMed ID: 21431323)
1. Arsenic trioxide may improve the prognosis of APL with ider(17)(q10): report of a rare adult case of acute promyelocytic leukemia with ider(17)(q10)t(15;17) showing poor response to all-trans retinoic acid.
Tong H; Li K; Mei C; Wang H; Chen Z; Jin J
Ann Hematol; 2011 Dec; 90(12):1493-4. PubMed ID: 21431323
[No Abstract] [Full Text] [Related]
2. All-trans-retinoic acid and arsenic trioxide as initial therapy for acute promyelocytic leukemia.
Quezada G; Kopp L; Estey E; Wells RJ
Pediatr Blood Cancer; 2008 Jul; 51(1):133-5. PubMed ID: 18293388
[TBL] [Abstract][Full Text] [Related]
3. Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).
Zhang T; Westervelt P; Hess JL
Mod Pathol; 2000 Sep; 13(9):954-61. PubMed ID: 11007035
[TBL] [Abstract][Full Text] [Related]
4. All-trans retinoic acid and arsenic trioxide resistance of acute promyelocytic leukemia with the variant STAT5B-RARA fusion gene.
Strehl S; König M; Boztug H; Cooper BW; Suzukawa K; Zhang SJ; Chen HY; Attarbaschi A; Dworzak MN
Leukemia; 2013 Jul; 27(7):1606-10. PubMed ID: 23271512
[No Abstract] [Full Text] [Related]
5. Combination brings long-term remission in acute promyelocytic leukemia refractory for both all-trans retinoic acid and arsenic trioxide.
Sasaki M; Sugimoto K; Isobe Y; Oshimi K
Eur J Haematol; 2008 Aug; 81(2):160. PubMed ID: 18363868
[No Abstract] [Full Text] [Related]
6. ider(17)(q10)t(15;17) associated with relapse and poor prognosis in a pediatric patient with acute promyelocytic leukemia.
Kim MJ; Yoon HS; Cho SY; Lee HJ; Suh JT; Lee J; Yoon HJ; Lee WI; Park TS
Cancer Genet Cytogenet; 2010 Sep; 201(2):116-21. PubMed ID: 20682396
[TBL] [Abstract][Full Text] [Related]
7. Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.
Vitoux D; Nasr R; de The H
Int J Biochem Cell Biol; 2007; 39(6):1063-70. PubMed ID: 17468032
[TBL] [Abstract][Full Text] [Related]
8. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia.
Zhang P
J Biol Regul Homeost Agents; 1999; 13(4):195-200. PubMed ID: 10703942
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report.
Bergstrom SK; Gillan E; Quinn JJ; Altman AJ
J Pediatr Hematol Oncol; 1998; 20(6):545-7. PubMed ID: 9856675
[TBL] [Abstract][Full Text] [Related]
10. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade D; Mistry AR; Solomon E; Guidez F
Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
[TBL] [Abstract][Full Text] [Related]
11. A single course of all-trans retinoic acid plus arsenic trioxide reached a long-term survival in a patient with newly diagnosed acute promyelocytic leukemia: a suggestion for reduction of treatment courses?
Yan J; Chen X; Shao J
Eur J Haematol; 2013 Nov; 91(5):470-1. PubMed ID: 23869721
[No Abstract] [Full Text] [Related]
12. Acute promyelocytic leukemia in childhood.
Gregory J; Feusner J
Curr Oncol Rep; 2009 Nov; 11(6):439-45. PubMed ID: 19840521
[TBL] [Abstract][Full Text] [Related]
13. Superiority of an arsenic trioxide-based regimen over a historic control combining all-trans retinoic acid plus intensive chemotherapy in the treatment of relapsed acute promyelocytic leukemia.
Thomas X; Pigneux A; Raffoux E; Huguet F; Caillot D; Fenaux P
Haematologica; 2006 Jul; 91(7):996-7. PubMed ID: 16757416
[TBL] [Abstract][Full Text] [Related]
14. Hemostatic abnormalities associated with acute promyelocytic leukemia and corrective effects of all-trans-retinoic acid or arsenic trioxide treatment.
Zhao W; Wang X; Guo W; Qu B; Wang H; Shen Z; Chen Z; Wang Z
Chin Med J (Engl); 2000 Mar; 113(3):236-40. PubMed ID: 11775254
[TBL] [Abstract][Full Text] [Related]
15. Autophagic degradation of an oncoprotein.
Bøe SO; Simonsen A
Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820
[TBL] [Abstract][Full Text] [Related]
16. Advances in management of acute promyelocytic leukemia with arsenic trioxide.
Ma J
Chin J Integr Med; 2007 Jun; 13(2):92-4. PubMed ID: 17609904
[No Abstract] [Full Text] [Related]
17. Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia.
Che-Pin Lin ; Huang MJ; Chang IY; Lin WY; Sheu YT
Leuk Lymphoma; 2000 Jun; 38(1-2):195-8. PubMed ID: 10811463
[TBL] [Abstract][Full Text] [Related]
18. [An analysis of the therapeutic effects and reactions in treating acute promyelocytic leukemia with intravenous arsenic trioxide or all-trans retinoic acid].
Zhang X; Yang L; Qiao Z
Zhonghua Nei Ke Za Zhi; 1999 Feb; 38(2):113-5. PubMed ID: 11798639
[TBL] [Abstract][Full Text] [Related]
19. Arsenic in the cerebrospinal fluid of a patient receiving arsenic trioxide for relapsed acute promyelocytic leukemia with CNS involvement.
Knipp S; Gattermann N; Schapira M; Käferstein H; Germing U
Leuk Res; 2007 Nov; 31(11):1585-7. PubMed ID: 17416415
[TBL] [Abstract][Full Text] [Related]
20. Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.
Shen Y; Fu YK; Zhu YM; Lou YJ; Gu ZH; Shi JY; Chen B; Chen C; Zhu HH; Hu J; Zhao WL; Mi JQ; Chen L; Zhu HM; Shen ZX; Jin J; Wang ZY; Li JM; Chen Z; Chen SJ
EBioMedicine; 2015 Jun; 2(6):563-71. PubMed ID: 26285909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
